Covaxin shows 'positive' results in phase 2/3 studies in US: Ocugen

If approved, will become the first India-developed vax to be commercialised in the US

Moving a step closer to commercialising the first India-developed vaccine in the US, Hyderabad-based Bharat Biotech’s partner Ocugen Inc. has announced positive top line data for the Covid vaccine candidate Covaxin (BBV152) from The phase 2/3 immuno-bridging study.

Nasdaq-listed Ocugen is Bharat Biotech’s partner to commercialise Covaxin in the US, Canada, and Mexico. The two entered into a partnership in February 2021 for the US market, and have since expanded the partnership to include Canadian and Mexico markets as well.

If the studies are successful in meeting endpoints and the US drug regulator approves Covaxin, it would be the first-ever